Gerard J. Nuovo

CS Diagnostics — Germany

Biochemistry, Genetics and Molecular Biology · Life Sciences

79h-index24.9kcitations310works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

MicroRNA in disease regulation(72), Cancer-related molecular mechanisms research(41), Virus-based gene therapy research(33), Circular RNAs in diseases(28), RNA modifications and cancer(23)

Publications310 total

Loss of ICOSL expression in the progression to cervical carcinoma
Proceedings of the National Academy of Sciences·2025Open Access
Nasopharyngeal carcinoma: a model cancer to understand tumor rejection
Signal Transduction and Targeted Therapy·2025· 2 citedOpen Access
<i>miR-155</i> impairs ICOSL and MHC-I expression in DLBCL lymphomas
Proceedings of the National Academy of Sciences·2025· 3 citedOpen Access
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
Journal of Hematology & Oncology·2025· 7 citedOpen Access
Pyoderma Gangrenosum Associated With Iatrogenic Interleukin 17A Blockade: A Report of Two Cases and a Review of the Literature
Journal of Cutaneous Pathology·2024Open Access
<i>MiR-155</i> -targeted IcosL controls tumor rejection
Proceedings of the National Academy of Sciences·2024· 6 citedOpen Access
Retraction: Methylation Mediated Silencing of MicroRNA-1 Gene and Its Role in Hepatocellular Carcinogenesis
Cancer Research·2023· 1 citedOpen Access
Indirect CLEM Identifies Nanoscale Remodeling Associated with Atrial Fibrillation in Diverse Etiologies, Enabling a Unified Therapeutic Approach
Microscopy and Microanalysis·2023Open Access
Supplementary Figures 1-4 from RETRACTED: Methylation Mediated Silencing of MicroRNA-1 Gene and Its Role in Hepatocellular Carcinogenesis
2023Open Access
Data from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
Data from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
supplemental legend from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
Supplementary table 1 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
Supplementary table 2 from A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2023Open Access
Supplementary Figure 4 from Fibulin-3 Promotes Glioma Growth and Resistance through a Novel Paracrine Regulation of Notch Signaling
2023Open Access
Supplementary Figures 1-7, Tables 1-2 from miR-221 Silencing Blocks Hepatocellular Carcinoma and Promotes Survival
2023Open Access
Supplementary Figure 1 from Fibulin-3 Promotes Glioma Growth and Resistance through a Novel Paracrine Regulation of Notch Signaling
2023Open Access
Supplementary Figure Legends 1-7 from Fibulin-3 Promotes Glioma Growth and Resistance through a Novel Paracrine Regulation of Notch Signaling
2023Open Access
page 1 of 16Next →

Frequent Co-authors

Carlo M. Croce(16), Hansjüerg Alder(8), Thomas D. Schmittgen(7), Stefano Volinia(7), Pierluigi Gasparini(6), Francesca Lovat(5), Melissa Crawford(5), Michela Garofalo(5), Gianpiero Di Leva(5), Tushar Patel(5), S. Patrick Nana‐Sinkam(5), Jinmai Jiang(4), Apollinaire Ngankeu(4), Cristian Taccioli(4), Chiara Braconi(4), Nicola Valeri(4), Jharna Datta(4), Huban Kutay(4), Kalpana Ghoshal(4), Sarmila Majumder(4)